A326030 Stock Overview
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, discovery, and development of drugs for the treatment of central nervous system disorders.
SK Biopharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₩86,600.00|
|52 Week High||₩137,500.00|
|52 Week Low||₩73,000.00|
|1 Month Change||-0.23%|
|3 Month Change||9.07%|
|1 Year Change||-23.02%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-31.81%|
Recent News & Updates
|A326030||KR Pharmaceuticals||KR Market|
Return vs Industry: A326030 exceeded the KR Pharmaceuticals industry which returned -26.6% over the past year.
Return vs Market: A326030 underperformed the KR Market which returned -14.2% over the past year.
|A326030 Average Weekly Movement||4.1%|
|Pharmaceuticals Industry Average Movement||4.4%|
|Market Average Movement||5.5%|
|10% most volatile stocks in KR Market||10.4%|
|10% least volatile stocks in KR Market||3.2%|
Stable Share Price: A326030 is less volatile than 75% of KR stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: A326030's weekly volatility (4%) has been stable over the past year.
About the Company
|2011||n/a||Jeong Woo Cho||https://www.skbp.com|
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, discovery, and development of drugs for the treatment of central nervous system disorders. The company is developing Cenobamate for the treatment of epilepsy; Solriamfetol for the treatment of excessive daytime sleepiness in narcolepsy or obstructive sleep apneal; Carisbamate that is in Phase 1b/2 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials to treat rare neurological disease. It is also developing SKL13865 that is in Phase 1 clinical trials to treat attention deficit/hyperactivity disorder; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder; and SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy.
SK Biopharmaceuticals Fundamentals Summary
|A326030 fundamental statistics|
Is A326030 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|A326030 income statement (TTM)|
|Cost of Revenue||₩22.34b|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||828.03|
|Net Profit Margin||15.49%|
How did A326030 perform over the long term?See historical performance and comparison
Is SK Biopharmaceuticals undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate A326030's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate A326030's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: A326030 is poor value based on its PE Ratio (104.6x) compared to the KR Pharmaceuticals industry average (25.6x).
PE vs Market: A326030 is poor value based on its PE Ratio (104.6x) compared to the KR market (14x).
Price to Earnings Growth Ratio
PEG Ratio: A326030 is poor value based on its PEG Ratio (5x)
Price to Book Ratio
PB vs Industry: A326030 is overvalued based on its PB Ratio (15.3x) compared to the KR Pharmaceuticals industry average (1.6x).
How is SK Biopharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: A326030's forecast earnings growth (20.8% per year) is above the savings rate (3.5%).
Earnings vs Market: A326030's earnings (20.8% per year) are forecast to grow faster than the KR market (14.7% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: A326030's revenue (11.5% per year) is forecast to grow faster than the KR market (9.7% per year).
High Growth Revenue: A326030's revenue (11.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: A326030's Return on Equity is forecast to be low in 3 years time (13.1%).
How has SK Biopharmaceuticals performed over the past 5 years?
Past Performance Score1/6
Past Performance Score 1/6
Growing Profit Margin
Earnings vs Industry
Last years revenue growth
Earnings and Revenue History
Quality Earnings: A326030 has a large one-off gain of ₩51.5B impacting its December 31 2021 financial results.
Growing Profit Margin: A326030 became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if A326030's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare A326030's past year earnings growth to its 5-year average as it has been trading publicly for less than 3 years.
Earnings vs Industry: A326030 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-10.9%).
Return on Equity
High ROE: A326030's Return on Equity (14.6%) is considered low.
How is SK Biopharmaceuticals's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: A326030's short term assets (₩471.2B) exceed its short term liabilities (₩148.3B).
Long Term Liabilities: A326030's short term assets (₩471.2B) exceed its long term liabilities (₩51.2B).
Debt to Equity History and Analysis
Debt Level: A326030 is debt free.
Reducing Debt: A326030 had no debt 5 years ago.
Debt Coverage: A326030 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: A326030 has no debt, therefore coverage of interest payments is not a concern.
What is SK Biopharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate A326030's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate A326030's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if A326030's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if A326030's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as A326030 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Jeong Woo Cho
Mr. Jeong Woo Cho, PhD, serves as Director at SK Biopharmaceuticals Co., Ltd. since March 16, 2017. He is the President & CEO at SK Biopharmaceuticals Co., Ltd and SK Life Science, Inc. since 2017.Mr. Cho...
Experienced Board: A326030's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
SK Biopharmaceuticals Co., Ltd.'s employee growth, exchange listings and data sources
- Name: SK Biopharmaceuticals Co., Ltd.
- Ticker: A326030
- Exchange: KOSE
- Founded: 2011
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₩6.782t
- Shares outstanding: 78.31m
- Website: https://www.skbp.com
- SK Biopharmaceuticals Co., Ltd.
- 221, Pangyoyeok-ro
- South Korea
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/23 00:00|
|End of Day Share Price||2022/05/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.